Cardiol Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Cardiol Therapeutics wird ein Gewinn- und Umsatzwachstum von 45.8% bzw. 75.7% pro Jahr prognostiziert, während der Gewinn pro Aktie um 48% pro Jahr wachsen soll.

Wichtige Informationen

36.4%

Wachstumsrate der Gewinne

38.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.3%
Wachstumsrate der Einnahmen	72.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	26 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:CRDL - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CAD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	4	-36	-30	-30	4
12/31/2025	N/A	-34	-18	-17	5
12/31/2024	N/A	-32	-19	-19	5
3/31/2024	N/A	-30	-22	-22	N/A
12/31/2023	N/A	-28	-25	-25	N/A
9/30/2023	N/A	-28	-31	-31	N/A
6/30/2023	N/A	-30	-30	-30	N/A
3/31/2023	N/A	-29	-27	-27	N/A
12/31/2022	N/A	-31	-27	-27	N/A
9/30/2022	N/A	-30	-19	-19	N/A
6/30/2022	N/A	-32	-23	-23	N/A
3/31/2022	0	-32	-27	-27	N/A
12/31/2021	0	-32	-24	-24	N/A
9/30/2021	0	-35	-22	-22	N/A
6/30/2021	0	-30	-19	-19	N/A
3/31/2021	N/A	-27	-14	-14	N/A
12/31/2020	N/A	-21	-9	-9	N/A
9/30/2020	N/A	-14	-10	-10	N/A
6/30/2020	N/A	-13	-9	-9	N/A
3/31/2020	N/A	-13	-10	-10	N/A
12/31/2019	N/A	-14	-12	-11	N/A
9/30/2019	N/A	-20	-17	-17	N/A
6/30/2019	N/A	-21	-16	-16	N/A
3/31/2019	N/A	-19	-15	-15	N/A
12/31/2018	N/A	-16	-11	-11	N/A
9/30/2018	N/A	-8	-3	-3	N/A
6/30/2018	N/A	-3	-2	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CRDL wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CRDL wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CRDL wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CRDL wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: CRDL wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CRDL in 3 Jahren voraussichtlich hoch sein wird

Cardiol Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

President recently bought US$101k worth of stock

Cardiol Therapeutics Inc., Annual General Meeting, Jul 26, 2024

Cardiol Therapeutics Inc. Announces It Has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Cardiol Therapeutics Inc. Announces Massachusetts General Hospital as the 8th Major Medical Centre Participating in MAvERIC-Pilot

New minor risk - Shareholder dilution

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Cardiol Therapeutics Inc. Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in Model of Heart Failure with Preserved Ejection Fraction

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in Archer, A Phase II Trial of Cardiolrx™ for the Treatment of Acute Myocarditis

High number of new and inexperienced directors

Cardiol Therapeutics Inc., Annual General Meeting, Jun 28, 2023

Cardiol Therapeutics Inc. Announces First Patient Enrolled in Phase II Study Evaluating Cardiolrx for the Treatment of Recurrent Pericarditis

Cardiol Therapeutics Inc. Announces the Initiation of a Phase II Open-Label Pilot Study (NCT05494788), to Investigate the Tolerance, Safety, and Efficacy of CardiolRx in Patients with Recurrent Pericarditis

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Cardiol Therapeutics Inc. Announces Study Results Demonstrating Protective Effects of Cardiolrx in A Model of Acute Pericarditis

Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating Cardiolrx Inhibits

Cardiol Therapeutics Inc. Announces First Patient Enrolled in Archer, A Phase II Clinical Trial of Cardiolrx(TM) for Treatment of Acute Myocarditis

Cardiol Therapeutics Inc. Announces Board Appointments

Cardiol Therapeutics Announces FDA Investigational New Drug Application Authorization for Multicenter Phase II Open-Label Pilot Study of Cardiolrx for Recurrent Pericarditis

Cardiol Therapeutics Inc., Annual General Meeting, Jun 28, 2022

Cardiol Therapeutics Inc. Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments in Lancer Trial

Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (Ind) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis

Cardiol Therapeutics Common Shares Class A Deleted from Other OTC

Cardiol Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 22.0032 million.

Cardiol Therapeutics Announces First Patient Enrolled in Lancer, A Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with Covid-19

Cardiol Therapeutics Inc Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase Ii/Iii Outcomes Trial in High-Risk Patients Hospitalized with Covid-19

Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company's Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with Covid-19

U.S. Food and Drug Administration Approves Cardiol Therapeutics Inc.'S Investigational New Drug Application to Commence A Phase II/III of CardiolRx

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken